Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3342695

CCCCC(CCCO)CCC(=O)O.O=C(O)C(F)(F)F

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.41
PLA2G2C Q5R387 1/20 0.39
AKR1B1 P15121 1/20 0.38
HDAC11 Q96DB2 6/20 0.38
HDAC3 O15379 2/20 0.38
HDAC1 Q13547 2/20 0.38
HDAC2 Q92769 2/20 0.38
HDAC8 Q9BY41 2/20 0.38
HDAC6 Q9UBN7 2/20 0.38
HDAC4 P56524 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
FAAH O00519 1/20 0.38
MAPT P10636 1/20 0.38
FFAR4 Q5NUL3 2/20 0.38
FFAR1 O14842 2/20 0.38
GPR84 Q9NQS5 6/20 0.37
PPARG P37231 6/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4629328 0.90 CA2 (0.48) CA2PLA2G2CAKR1B1HDAC11FFAR4
SCHEMBL6830568 0.84 FFAR4 (0.52) AKR1B1HDAC11FFAR4FFAR1GPR84
SCHEMBL8984375 0.83 FFAR4 (0.50) CA2PLA2G2CHDAC11FFAR4FFAR1
SCHEMBL3930979 0.83 CAMK2A (0.44) CA2AKR1B1HDAC11HDAC3HDAC1
SCHEMBL4875928 0.82 CA2 (0.55) CA2PLA2G2CAKR1B1HDAC11HDAC3
SCHEMBL5077959 0.81 FFAR4 (0.53) PLA2G2CAKR1B1HDAC11FFAR4FFAR1
Trifluoroacetic Acid SCHEMBL720969 0.80 ACE2 (0.46) CA2FAAHMAPTALDH1A1MEN1
SCHEMBL5082422 0.80 FFAR4 (0.55) AKR1B1HDAC11FFAR4FFAR1GPR84
SCHEMBL6720816 0.79 CA2 (0.52) CA2PLA2G2CAKR1B1HDAC11FFAR4
SCHEMBL28184368 0.79 FFAR4 (0.57) CA2PLA2G2CAKR1B1HDAC11FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172443-B1 METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE HAMARI CHEMICALS LTD (JP) 2013-03-27 EP disclosed
US-8222452-B2 Method for producing optically active amines HAMARI CHEMICALS, LTD. (JP) 2012-07-17 US disclosed
US-20100160636-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE AMINES HAMARI CHEMICALS, LTD. (JP) 2010-06-24 US disclosed
EP-2172443-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE Hamari Chemicals, Ltd. (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160636-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE AMINES INMT, HNMT, PADI3 CA2 3190/4885PLA2G2C 2845/4885AKR1B1 1729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.